SlideShare a Scribd company logo

Hypertension

1 of 42
ANTIHYPERTENSIVE DRUGS IN
SPECIAL SITUATIONS
CURRENT RECOMMENDATIONS FOR BP GOALS
JNC 7 (Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood) Pressure
 Goal BP <140/90
 Goal with Diabetes or CKD <130/80
http://www.nhlbi.nih.gov/guidelines/hypertension/
ANTIHYPERTENSIVES IN
SPECIAL POPULATION
SPECIAL POPULATIONS INCLUDE
o Diabetes
o Cardiovascular Disease
oCCF
oIschaemic heart disease
oBradycardia
oPeripheral Vascular disease
o Elderly
o Chronic Kidney Disease
o Hypertensive crisis
Other Situations
oChildren and Adolescents
oPregnancy
oHormone replacement therapy
oDyslipidemia
oAsthma and COPD
oCerebrovascular disease
oLiver disease
oGout
oPsoriasis
oScleroderma with Reynaud's phenomenon
HYPERTENSION IN DIABETES

Recommended

Hypertension: New Concepts, Guidelines, and Clinical Management Hypertensio...
Hypertension: New Concepts, Guidelines, and Clinical Management 	 Hypertensio...Hypertension: New Concepts, Guidelines, and Clinical Management 	 Hypertensio...
Hypertension: New Concepts, Guidelines, and Clinical Management Hypertensio...MedicineAndFamily
 
Heart failure update
Heart failure updateHeart failure update
Heart failure updateSushant Yadav
 
Hypertension in special situation
Hypertension in special situationHypertension in special situation
Hypertension in special situationRashna Sharmin
 
Pharmacotherapy of heart failure
Pharmacotherapy of heart failurePharmacotherapy of heart failure
Pharmacotherapy of heart failureDr. Shivesh Gupta
 
how low to go with LDL
how low to go with LDL how low to go with LDL
how low to go with LDL Praveen Nagula
 
2022 Guideline for the Management of Heart Failure Clinical Update.pptx
2022 Guideline for the Management of Heart Failure Clinical Update.pptx2022 Guideline for the Management of Heart Failure Clinical Update.pptx
2022 Guideline for the Management of Heart Failure Clinical Update.pptxsubhankar16
 
Hypertension Management - ESC/ESH 2018 guidelines
Hypertension Management - ESC/ESH 2018 guidelinesHypertension Management - ESC/ESH 2018 guidelines
Hypertension Management - ESC/ESH 2018 guidelinesPardhuBharath1
 

More Related Content

What's hot

2021 ESC Guidelines for Heart Failure - What's New and How much to Adapt
2021 ESC Guidelines for Heart Failure - What's New and How much to Adapt2021 ESC Guidelines for Heart Failure - What's New and How much to Adapt
2021 ESC Guidelines for Heart Failure - What's New and How much to AdaptDr. Md. Samiul Haque
 
Combination therapy in hypertension
Combination therapy in hypertensionCombination therapy in hypertension
Combination therapy in hypertensionDr Pradip Mate
 
Angiotensin Receptor Neprilysin + Valsartan
Angiotensin Receptor Neprilysin + ValsartanAngiotensin Receptor Neprilysin + Valsartan
Angiotensin Receptor Neprilysin + ValsartanJai Parekh
 
Newer trends in heart failure by Dr. Vaibhav Yawalkar MD DM Cardiology, Consu...
Newer trends in heart failure by Dr. Vaibhav Yawalkar MD DM Cardiology, Consu...Newer trends in heart failure by Dr. Vaibhav Yawalkar MD DM Cardiology, Consu...
Newer trends in heart failure by Dr. Vaibhav Yawalkar MD DM Cardiology, Consu...vaibhavyawalkar
 
Update in hypertension management
Update in hypertension managementUpdate in hypertension management
Update in hypertension managementTarek Khalil
 
Management of dm in ckd
Management of dm in ckdManagement of dm in ckd
Management of dm in ckdPraveen Nagula
 
Dyslipidemia management an evidence based approach
Dyslipidemia management an evidence based approachDyslipidemia management an evidence based approach
Dyslipidemia management an evidence based approachDr Vivek Baliga
 
2018 ESC/ESH Guidelines for the management of arterial hypertension
2018 ESC/ESH Guidelines for the management of arterial hypertension2018 ESC/ESH Guidelines for the management of arterial hypertension
2018 ESC/ESH Guidelines for the management of arterial hypertensionJulfikar Saif
 
Cardiorenal Syndrome
Cardiorenal SyndromeCardiorenal Syndrome
Cardiorenal SyndromeSujay Iyer
 
Strategies for the use of cardioselective beta blockers in cv continuum
Strategies for the use of cardioselective beta blockers in cv continuum Strategies for the use of cardioselective beta blockers in cv continuum
Strategies for the use of cardioselective beta blockers in cv continuum scsinha
 
Ppt on hypertension
Ppt on hypertensionPpt on hypertension
Ppt on hypertensionpawan kumar
 
Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials ...
Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials  ...Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials  ...
Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials ...magdy elmasry
 
Hypertension management 2018
Hypertension management  2018Hypertension management  2018
Hypertension management 2018Monkez M Yousif
 
Antiplatelet therapy
Antiplatelet therapyAntiplatelet therapy
Antiplatelet therapyArindam Pande
 

What's hot (20)

Resistant hypertension
Resistant hypertensionResistant hypertension
Resistant hypertension
 
2021 ESC Guidelines for Heart Failure - What's New and How much to Adapt
2021 ESC Guidelines for Heart Failure - What's New and How much to Adapt2021 ESC Guidelines for Heart Failure - What's New and How much to Adapt
2021 ESC Guidelines for Heart Failure - What's New and How much to Adapt
 
Congestive heart failure
Congestive heart failureCongestive heart failure
Congestive heart failure
 
Combination therapy in hypertension
Combination therapy in hypertensionCombination therapy in hypertension
Combination therapy in hypertension
 
Angiotensin Receptor Neprilysin + Valsartan
Angiotensin Receptor Neprilysin + ValsartanAngiotensin Receptor Neprilysin + Valsartan
Angiotensin Receptor Neprilysin + Valsartan
 
Newer trends in heart failure by Dr. Vaibhav Yawalkar MD DM Cardiology, Consu...
Newer trends in heart failure by Dr. Vaibhav Yawalkar MD DM Cardiology, Consu...Newer trends in heart failure by Dr. Vaibhav Yawalkar MD DM Cardiology, Consu...
Newer trends in heart failure by Dr. Vaibhav Yawalkar MD DM Cardiology, Consu...
 
Update in hypertension management
Update in hypertension managementUpdate in hypertension management
Update in hypertension management
 
Management of dm in ckd
Management of dm in ckdManagement of dm in ckd
Management of dm in ckd
 
HF update 2021
HF update 2021HF update 2021
HF update 2021
 
Dyslipidemia management an evidence based approach
Dyslipidemia management an evidence based approachDyslipidemia management an evidence based approach
Dyslipidemia management an evidence based approach
 
2018 ESC/ESH Guidelines for the management of arterial hypertension
2018 ESC/ESH Guidelines for the management of arterial hypertension2018 ESC/ESH Guidelines for the management of arterial hypertension
2018 ESC/ESH Guidelines for the management of arterial hypertension
 
Hypertension (HTN)
Hypertension (HTN)Hypertension (HTN)
Hypertension (HTN)
 
Cardiorenal Syndrome
Cardiorenal SyndromeCardiorenal Syndrome
Cardiorenal Syndrome
 
Telmisartan combination uses
Telmisartan combination usesTelmisartan combination uses
Telmisartan combination uses
 
Strategies for the use of cardioselective beta blockers in cv continuum
Strategies for the use of cardioselective beta blockers in cv continuum Strategies for the use of cardioselective beta blockers in cv continuum
Strategies for the use of cardioselective beta blockers in cv continuum
 
Ticagrelor
TicagrelorTicagrelor
Ticagrelor
 
Ppt on hypertension
Ppt on hypertensionPpt on hypertension
Ppt on hypertension
 
Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials ...
Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials  ...Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials  ...
Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials ...
 
Hypertension management 2018
Hypertension management  2018Hypertension management  2018
Hypertension management 2018
 
Antiplatelet therapy
Antiplatelet therapyAntiplatelet therapy
Antiplatelet therapy
 

Viewers also liked

Treatment Of Hypertension In Special Situation Modified Fina Lc
Treatment Of Hypertension In Special Situation Modified Fina LcTreatment Of Hypertension In Special Situation Modified Fina Lc
Treatment Of Hypertension In Special Situation Modified Fina Lcdrmisbah83
 
hypertension anesthesia, general management. antihypertensive pharmacology
hypertension anesthesia, general management. antihypertensive pharmacologyhypertension anesthesia, general management. antihypertensive pharmacology
hypertension anesthesia, general management. antihypertensive pharmacologyAbayneh Belihun
 
Proximal tibia fracture
Proximal tibia fractureProximal tibia fracture
Proximal tibia fracturevisheshrohatgi
 
Bp targets 2014-2015
Bp targets 2014-2015Bp targets 2014-2015
Bp targets 2014-2015magdy elmasry
 
Prevention of stroke - Dự phòng đột quỵ não
Prevention of stroke - Dự phòng đột quỵ nãoPrevention of stroke - Dự phòng đột quỵ não
Prevention of stroke - Dự phòng đột quỵ nãodangphucduc
 
1.6.2 Pharmacologic Treatment
1.6.2 Pharmacologic Treatment1.6.2 Pharmacologic Treatment
1.6.2 Pharmacologic Treatmentmedicinaudm
 
UNC Center for Heart & Vascular Care 'Go Red For Women' 2015
UNC Center for Heart & Vascular Care 'Go Red For Women' 2015UNC Center for Heart & Vascular Care 'Go Red For Women' 2015
UNC Center for Heart & Vascular Care 'Go Red For Women' 2015UNCHeartandVascular
 
Cardiovascular examination (format only)
Cardiovascular examination (format only)Cardiovascular examination (format only)
Cardiovascular examination (format only)visheshrohatgi
 
1 resistant hypertension
1 resistant hypertension1 resistant hypertension
1 resistant hypertensionthozie02
 
Prevention of heart disease
Prevention of heart diseasePrevention of heart disease
Prevention of heart diseaseDr. Armaan Singh
 
Hypertension conbinsation therapy 2014
Hypertension conbinsation therapy 2014Hypertension conbinsation therapy 2014
Hypertension conbinsation therapy 2014Muhamed Al Rohani
 
Antihypertensive drugs
Antihypertensive drugsAntihypertensive drugs
Antihypertensive drugsKarun Kumar
 

Viewers also liked (20)

Cations and anions
Cations and anionsCations and anions
Cations and anions
 
Vasculitis
VasculitisVasculitis
Vasculitis
 
Treatment Of Hypertension In Special Situation Modified Fina Lc
Treatment Of Hypertension In Special Situation Modified Fina LcTreatment Of Hypertension In Special Situation Modified Fina Lc
Treatment Of Hypertension In Special Situation Modified Fina Lc
 
hypertension anesthesia, general management. antihypertensive pharmacology
hypertension anesthesia, general management. antihypertensive pharmacologyhypertension anesthesia, general management. antihypertensive pharmacology
hypertension anesthesia, general management. antihypertensive pharmacology
 
Journal Club
Journal ClubJournal Club
Journal Club
 
Proximal tibia fracture
Proximal tibia fractureProximal tibia fracture
Proximal tibia fracture
 
Are+all+sartans+equal
Are+all+sartans+equalAre+all+sartans+equal
Are+all+sartans+equal
 
Bp targets 2014-2015
Bp targets 2014-2015Bp targets 2014-2015
Bp targets 2014-2015
 
Lekcia antyhiper
Lekcia antyhiperLekcia antyhiper
Lekcia antyhiper
 
Prevention of stroke - Dự phòng đột quỵ não
Prevention of stroke - Dự phòng đột quỵ nãoPrevention of stroke - Dự phòng đột quỵ não
Prevention of stroke - Dự phòng đột quỵ não
 
Ppi in cardiology
Ppi in cardiologyPpi in cardiology
Ppi in cardiology
 
1.6.2 Pharmacologic Treatment
1.6.2 Pharmacologic Treatment1.6.2 Pharmacologic Treatment
1.6.2 Pharmacologic Treatment
 
worlb bank
worlb bankworlb bank
worlb bank
 
UNC Center for Heart & Vascular Care 'Go Red For Women' 2015
UNC Center for Heart & Vascular Care 'Go Red For Women' 2015UNC Center for Heart & Vascular Care 'Go Red For Women' 2015
UNC Center for Heart & Vascular Care 'Go Red For Women' 2015
 
Cardiovascular examination (format only)
Cardiovascular examination (format only)Cardiovascular examination (format only)
Cardiovascular examination (format only)
 
1 resistant hypertension
1 resistant hypertension1 resistant hypertension
1 resistant hypertension
 
Prevention of heart disease
Prevention of heart diseasePrevention of heart disease
Prevention of heart disease
 
Hypertension conbinsation therapy 2014
Hypertension conbinsation therapy 2014Hypertension conbinsation therapy 2014
Hypertension conbinsation therapy 2014
 
Guidelines in Fracture Management - Proximal Tibia by Babhulkar
Guidelines in Fracture Management - Proximal Tibia by BabhulkarGuidelines in Fracture Management - Proximal Tibia by Babhulkar
Guidelines in Fracture Management - Proximal Tibia by Babhulkar
 
Antihypertensive drugs
Antihypertensive drugsAntihypertensive drugs
Antihypertensive drugs
 

Similar to Hypertension

Combination Therapy In Hypertension - Dr Vivek Baliga Presentation
Combination Therapy In Hypertension - Dr Vivek Baliga PresentationCombination Therapy In Hypertension - Dr Vivek Baliga Presentation
Combination Therapy In Hypertension - Dr Vivek Baliga PresentationDr Vivek Baliga
 
combinatintherapyhypertension-baliga.pdf
combinatintherapyhypertension-baliga.pdfcombinatintherapyhypertension-baliga.pdf
combinatintherapyhypertension-baliga.pdfAshutoshChaturvedi36
 
Hypertension; Basics- Recommendations - Special Situations
Hypertension; Basics-  Recommendations - Special SituationsHypertension; Basics-  Recommendations - Special Situations
Hypertension; Basics- Recommendations - Special SituationsRajat Biswas
 
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...O. E.Nyandi PhD
 
Joint national committe 7
Joint national committe 7Joint national committe 7
Joint national committe 7Noel Isaac
 
Hypertension according to harrison
Hypertension according to harrison Hypertension according to harrison
Hypertension according to harrison رازي خوري
 
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...O. E.Nyandi PhD
 
PHARMACOTHERAPY POINTERS FOR HTN (MALAYSIAN CPGs).pdf
PHARMACOTHERAPY POINTERS FOR HTN (MALAYSIAN CPGs).pdfPHARMACOTHERAPY POINTERS FOR HTN (MALAYSIAN CPGs).pdf
PHARMACOTHERAPY POINTERS FOR HTN (MALAYSIAN CPGs).pdfsamthamby79
 
2017 ACC/AHA Hypertension guidelines
2017 ACC/AHA Hypertension guidelines 2017 ACC/AHA Hypertension guidelines
2017 ACC/AHA Hypertension guidelines Eugenio Santoro
 
2017 ACC AHA guidelines on management of systemic hypertension
2017 ACC AHA guidelines on management of systemic hypertension2017 ACC AHA guidelines on management of systemic hypertension
2017 ACC AHA guidelines on management of systemic hypertensionVasif Mayan
 
HYPERTENSIVE NEPHROPATHY.pptx
HYPERTENSIVE NEPHROPATHY.pptxHYPERTENSIVE NEPHROPATHY.pptx
HYPERTENSIVE NEPHROPATHY.pptxMariaMahamed
 
Treatment of Hypertension YAKES.ppt
Treatment of Hypertension YAKES.pptTreatment of Hypertension YAKES.ppt
Treatment of Hypertension YAKES.pptmarissaqurniati
 
Hypertension pharmacotherapy part 2 ppt
Hypertension pharmacotherapy part 2 pptHypertension pharmacotherapy part 2 ppt
Hypertension pharmacotherapy part 2 pptPranatiChavan
 

Similar to Hypertension (20)

Combination Therapy In Hypertension - Dr Vivek Baliga Presentation
Combination Therapy In Hypertension - Dr Vivek Baliga PresentationCombination Therapy In Hypertension - Dr Vivek Baliga Presentation
Combination Therapy In Hypertension - Dr Vivek Baliga Presentation
 
combinatintherapyhypertension-baliga.pdf
combinatintherapyhypertension-baliga.pdfcombinatintherapyhypertension-baliga.pdf
combinatintherapyhypertension-baliga.pdf
 
Hypertension; Basics- Recommendations - Special Situations
Hypertension; Basics-  Recommendations - Special SituationsHypertension; Basics-  Recommendations - Special Situations
Hypertension; Basics- Recommendations - Special Situations
 
2ry htn
2ry htn2ry htn
2ry htn
 
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...
 
Hypertension Management
Hypertension ManagementHypertension Management
Hypertension Management
 
Joint national committe 7
Joint national committe 7Joint national committe 7
Joint national committe 7
 
Hypertension according to harrison
Hypertension according to harrison Hypertension according to harrison
Hypertension according to harrison
 
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...
 
Management and prevention of T2DM and Hypertension
Management and prevention of T2DM and HypertensionManagement and prevention of T2DM and Hypertension
Management and prevention of T2DM and Hypertension
 
PHARMACOTHERAPY POINTERS FOR HTN (MALAYSIAN CPGs).pdf
PHARMACOTHERAPY POINTERS FOR HTN (MALAYSIAN CPGs).pdfPHARMACOTHERAPY POINTERS FOR HTN (MALAYSIAN CPGs).pdf
PHARMACOTHERAPY POINTERS FOR HTN (MALAYSIAN CPGs).pdf
 
2017 ACC/AHA Hypertension guidelines
2017 ACC/AHA Hypertension guidelines 2017 ACC/AHA Hypertension guidelines
2017 ACC/AHA Hypertension guidelines
 
2017 ACC AHA guidelines on management of systemic hypertension
2017 ACC AHA guidelines on management of systemic hypertension2017 ACC AHA guidelines on management of systemic hypertension
2017 ACC AHA guidelines on management of systemic hypertension
 
HYPERTENSIVE NEPHROPATHY.pptx
HYPERTENSIVE NEPHROPATHY.pptxHYPERTENSIVE NEPHROPATHY.pptx
HYPERTENSIVE NEPHROPATHY.pptx
 
Hypertension
HypertensionHypertension
Hypertension
 
Treatment of Hypertension YAKES.ppt
Treatment of Hypertension YAKES.pptTreatment of Hypertension YAKES.ppt
Treatment of Hypertension YAKES.ppt
 
Aha new guidelines
Aha new guidelinesAha new guidelines
Aha new guidelines
 
Hypertension
HypertensionHypertension
Hypertension
 
Mellss yr4 primary care hypertension
Mellss yr4 primary care hypertensionMellss yr4 primary care hypertension
Mellss yr4 primary care hypertension
 
Hypertension pharmacotherapy part 2 ppt
Hypertension pharmacotherapy part 2 pptHypertension pharmacotherapy part 2 ppt
Hypertension pharmacotherapy part 2 ppt
 

Recently uploaded

PAEDIATRICS RHEMATOLOGY PROTOCOLS SHEET FOR PEDIATRICS ORTHOPAEDICS
PAEDIATRICS RHEMATOLOGY PROTOCOLS SHEET FOR PEDIATRICS ORTHOPAEDICSPAEDIATRICS RHEMATOLOGY PROTOCOLS SHEET FOR PEDIATRICS ORTHOPAEDICS
PAEDIATRICS RHEMATOLOGY PROTOCOLS SHEET FOR PEDIATRICS ORTHOPAEDICSDr.Shrikrushna Sobaji
 
GROSS ANATOMY OF CAECUM & APPENDIX DR VKVS.ppt
GROSS ANATOMY OF CAECUM & APPENDIX DR VKVS.pptGROSS ANATOMY OF CAECUM & APPENDIX DR VKVS.ppt
GROSS ANATOMY OF CAECUM & APPENDIX DR VKVS.pptDr Vinay KV Shetty
 
PTERYGIUM ,clinical picture and its management.pptx
PTERYGIUM ,clinical picture and its management.pptxPTERYGIUM ,clinical picture and its management.pptx
PTERYGIUM ,clinical picture and its management.pptxvideosfildr
 
Influenza.pptx Department of Physiotherapy, SHUATS, Prayagraj
Influenza.pptx Department of Physiotherapy, SHUATS, PrayagrajInfluenza.pptx Department of Physiotherapy, SHUATS, Prayagraj
Influenza.pptx Department of Physiotherapy, SHUATS, PrayagrajSurabhi Srivastava
 
Population of India and Family welfare programme.pptx
Population of India and Family welfare programme.pptxPopulation of India and Family welfare programme.pptx
Population of India and Family welfare programme.pptxDr. Dheeraj Kumar
 
Artificial Radionuclide Generators in Medicine Applications in Radiotherapy.pptx
Artificial Radionuclide Generators in Medicine Applications in Radiotherapy.pptxArtificial Radionuclide Generators in Medicine Applications in Radiotherapy.pptx
Artificial Radionuclide Generators in Medicine Applications in Radiotherapy.pptxDr. Dheeraj Kumar
 
(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj
(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj
(DENGUE).pptx Department of Physiotherapy, SHUATS, PrayagrajSurabhi Srivastava
 
Autism and Savant Syndrome|Study|The Good doctor .pptx
Autism and Savant Syndrome|Study|The Good doctor .pptxAutism and Savant Syndrome|Study|The Good doctor .pptx
Autism and Savant Syndrome|Study|The Good doctor .pptxScripted Symptoms
 
Work-role of Radiation Therapists in the Consequences of Adaptive Radiotherap...
Work-role of Radiation Therapists in the Consequences of Adaptive Radiotherap...Work-role of Radiation Therapists in the Consequences of Adaptive Radiotherap...
Work-role of Radiation Therapists in the Consequences of Adaptive Radiotherap...Subrata Roy
 
Best neurologist in jalandhar Punjab India
Best neurologist in jalandhar Punjab IndiaBest neurologist in jalandhar Punjab India
Best neurologist in jalandhar Punjab IndiaNHS Hospital
 
RADIATION THERAPY IN BILIARY TRACT CANCER
RADIATION THERAPY IN BILIARY TRACT CANCERRADIATION THERAPY IN BILIARY TRACT CANCER
RADIATION THERAPY IN BILIARY TRACT CANCERKanhu Charan
 
Measles.pptx Department of Physiotherapy, SHUATS, Prayagraj
Measles.pptx Department of Physiotherapy, SHUATS, PrayagrajMeasles.pptx Department of Physiotherapy, SHUATS, Prayagraj
Measles.pptx Department of Physiotherapy, SHUATS, PrayagrajSurabhi Srivastava
 
Hydrocele and tumors of testis Introduction.pptx
Hydrocele and tumors of testis Introduction.pptxHydrocele and tumors of testis Introduction.pptx
Hydrocele and tumors of testis Introduction.pptxSizan Thapa
 
Macquarie Neurosurgery Journal Club 2022 PPT
Macquarie Neurosurgery Journal Club 2022 PPTMacquarie Neurosurgery Journal Club 2022 PPT
Macquarie Neurosurgery Journal Club 2022 PPTMQ_Library
 
Psychedelic Treatment Planning: Opportunities in Integrated Care
Psychedelic Treatment Planning: Opportunities in Integrated CarePsychedelic Treatment Planning: Opportunities in Integrated Care
Psychedelic Treatment Planning: Opportunities in Integrated CareBrian Peacock
 
Namburi phased spot test - NPST To identify bhasma and sindhura - A Qualitat...
Namburi phased spot test - NPST  To identify bhasma and sindhura - A Qualitat...Namburi phased spot test - NPST  To identify bhasma and sindhura - A Qualitat...
Namburi phased spot test - NPST To identify bhasma and sindhura - A Qualitat...Dr. Madduru Muni Haritha
 
Bedside Utility of Liaoning Score a Non-Invasive As Predictor of Esophageal V...
Bedside Utility of Liaoning Score a Non-Invasive As Predictor of Esophageal V...Bedside Utility of Liaoning Score a Non-Invasive As Predictor of Esophageal V...
Bedside Utility of Liaoning Score a Non-Invasive As Predictor of Esophageal V...semualkaira
 
GERIATRIC PHARMACOLOGY Geriatric pharmacology is a specialized field focusing...
GERIATRIC PHARMACOLOGY Geriatric pharmacology is a specialized field focusing...GERIATRIC PHARMACOLOGY Geriatric pharmacology is a specialized field focusing...
GERIATRIC PHARMACOLOGY Geriatric pharmacology is a specialized field focusing...Abhinav S
 
Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...
Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...
Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...Golden Helix
 

Recently uploaded (20)

PAEDIATRICS RHEMATOLOGY PROTOCOLS SHEET FOR PEDIATRICS ORTHOPAEDICS
PAEDIATRICS RHEMATOLOGY PROTOCOLS SHEET FOR PEDIATRICS ORTHOPAEDICSPAEDIATRICS RHEMATOLOGY PROTOCOLS SHEET FOR PEDIATRICS ORTHOPAEDICS
PAEDIATRICS RHEMATOLOGY PROTOCOLS SHEET FOR PEDIATRICS ORTHOPAEDICS
 
GROSS ANATOMY OF CAECUM & APPENDIX DR VKVS.ppt
GROSS ANATOMY OF CAECUM & APPENDIX DR VKVS.pptGROSS ANATOMY OF CAECUM & APPENDIX DR VKVS.ppt
GROSS ANATOMY OF CAECUM & APPENDIX DR VKVS.ppt
 
PTERYGIUM ,clinical picture and its management.pptx
PTERYGIUM ,clinical picture and its management.pptxPTERYGIUM ,clinical picture and its management.pptx
PTERYGIUM ,clinical picture and its management.pptx
 
Influenza.pptx Department of Physiotherapy, SHUATS, Prayagraj
Influenza.pptx Department of Physiotherapy, SHUATS, PrayagrajInfluenza.pptx Department of Physiotherapy, SHUATS, Prayagraj
Influenza.pptx Department of Physiotherapy, SHUATS, Prayagraj
 
Population of India and Family welfare programme.pptx
Population of India and Family welfare programme.pptxPopulation of India and Family welfare programme.pptx
Population of India and Family welfare programme.pptx
 
Artificial Radionuclide Generators in Medicine Applications in Radiotherapy.pptx
Artificial Radionuclide Generators in Medicine Applications in Radiotherapy.pptxArtificial Radionuclide Generators in Medicine Applications in Radiotherapy.pptx
Artificial Radionuclide Generators in Medicine Applications in Radiotherapy.pptx
 
(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj
(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj
(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj
 
Autism and Savant Syndrome|Study|The Good doctor .pptx
Autism and Savant Syndrome|Study|The Good doctor .pptxAutism and Savant Syndrome|Study|The Good doctor .pptx
Autism and Savant Syndrome|Study|The Good doctor .pptx
 
Work-role of Radiation Therapists in the Consequences of Adaptive Radiotherap...
Work-role of Radiation Therapists in the Consequences of Adaptive Radiotherap...Work-role of Radiation Therapists in the Consequences of Adaptive Radiotherap...
Work-role of Radiation Therapists in the Consequences of Adaptive Radiotherap...
 
Best neurologist in jalandhar Punjab India
Best neurologist in jalandhar Punjab IndiaBest neurologist in jalandhar Punjab India
Best neurologist in jalandhar Punjab India
 
RADIATION THERAPY IN BILIARY TRACT CANCER
RADIATION THERAPY IN BILIARY TRACT CANCERRADIATION THERAPY IN BILIARY TRACT CANCER
RADIATION THERAPY IN BILIARY TRACT CANCER
 
Measles.pptx Department of Physiotherapy, SHUATS, Prayagraj
Measles.pptx Department of Physiotherapy, SHUATS, PrayagrajMeasles.pptx Department of Physiotherapy, SHUATS, Prayagraj
Measles.pptx Department of Physiotherapy, SHUATS, Prayagraj
 
Hydrocele and tumors of testis Introduction.pptx
Hydrocele and tumors of testis Introduction.pptxHydrocele and tumors of testis Introduction.pptx
Hydrocele and tumors of testis Introduction.pptx
 
A rare case of Omental & Fibroid Torsion
A rare case of Omental & Fibroid TorsionA rare case of Omental & Fibroid Torsion
A rare case of Omental & Fibroid Torsion
 
Macquarie Neurosurgery Journal Club 2022 PPT
Macquarie Neurosurgery Journal Club 2022 PPTMacquarie Neurosurgery Journal Club 2022 PPT
Macquarie Neurosurgery Journal Club 2022 PPT
 
Psychedelic Treatment Planning: Opportunities in Integrated Care
Psychedelic Treatment Planning: Opportunities in Integrated CarePsychedelic Treatment Planning: Opportunities in Integrated Care
Psychedelic Treatment Planning: Opportunities in Integrated Care
 
Namburi phased spot test - NPST To identify bhasma and sindhura - A Qualitat...
Namburi phased spot test - NPST  To identify bhasma and sindhura - A Qualitat...Namburi phased spot test - NPST  To identify bhasma and sindhura - A Qualitat...
Namburi phased spot test - NPST To identify bhasma and sindhura - A Qualitat...
 
Bedside Utility of Liaoning Score a Non-Invasive As Predictor of Esophageal V...
Bedside Utility of Liaoning Score a Non-Invasive As Predictor of Esophageal V...Bedside Utility of Liaoning Score a Non-Invasive As Predictor of Esophageal V...
Bedside Utility of Liaoning Score a Non-Invasive As Predictor of Esophageal V...
 
GERIATRIC PHARMACOLOGY Geriatric pharmacology is a specialized field focusing...
GERIATRIC PHARMACOLOGY Geriatric pharmacology is a specialized field focusing...GERIATRIC PHARMACOLOGY Geriatric pharmacology is a specialized field focusing...
GERIATRIC PHARMACOLOGY Geriatric pharmacology is a specialized field focusing...
 
Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...
Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...
Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...
 

Hypertension

  • 2. CURRENT RECOMMENDATIONS FOR BP GOALS JNC 7 (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood) Pressure  Goal BP <140/90  Goal with Diabetes or CKD <130/80 http://www.nhlbi.nih.gov/guidelines/hypertension/
  • 4. SPECIAL POPULATIONS INCLUDE o Diabetes o Cardiovascular Disease oCCF oIschaemic heart disease oBradycardia oPeripheral Vascular disease o Elderly o Chronic Kidney Disease o Hypertensive crisis
  • 5. Other Situations oChildren and Adolescents oPregnancy oHormone replacement therapy oDyslipidemia oAsthma and COPD oCerebrovascular disease oLiver disease oGout oPsoriasis oScleroderma with Reynaud's phenomenon
  • 7. HYPERTENSION IN DIABETES  JNC 7 Guidelines say: Treat to <130/80  Evidence says: No renal or cardiovascular benefit with lower BP  ACE/ARB therapy do improve renal outcomes in patients with proteinuria including microalbuminuria  New ICSI guideline: <140/85 (consider <130/80 in patients with proteinuria) www.icsi.org
  • 8. TREATMENT CHEP 2012 Threshold equal or over 130/80 mmHg and Target below 130/80 mmHg with Nephropathy* *Urinary albumin to creatinine ratio > 2.0 mg/mmol in men or > 2.8mg/mmol in women* Diabetes without Nephropathy** Isolated Systolic Hypertension Systolic- diastolic Hypertension * based on at least 2 of 3 measurements A combination of 2 first line drugs may be considered as initial therapy if the blood pressure is >20 mmHg systolic or >10 mmHg diastolic above target Combinations of an ACEI with an ARB are specifically not recommended in the absence of proteinuria
  • 9. If Creatinine over 150 µmol/L or creatinine clearance below 30 ml/min ( 0.5 ml/sec), a loop diuretic should be substituted for a thiazide diuretic if control of volume is desired THRESHOLD equal or over 130/80 mmHg and TARGET below 130/80 mmHg DIABETES with Nephropathy ACE Inhibitor or ARB IF ACEI and ARB are contraindicated or not tolerated, SUBSTITUTE • Long-acting CCB or • Thiazide diuretic Addition of one or more of Long-acting CCB or Thiazide diuretic 3 - 4 drugs combination may be needed Monitor serum potassium and creatinine carefully in patients with CKD prescribed an ACEI or ARB CHEP 2012
  • 10. 1. ACE Inhibitor or ARB or 2. Dihydropyridine CCB or Thiazide diuretic IF ACE Inhibitor and ARB and DHP-CCB and Thiazide are contraindicated or not tolerated, SUBSTITUTE • Cardioselective BB* or • Long-acting NON DHP-CCB More than 3 drugs may be needed to reach target values for diabetic patients * Cardioselective BB: Acebutolol, Atenolol, Bisoprolol , Metoprolol Threshold equal or over 130/80 mmHg and TARGET below 130/80 mmHg Combination of first line agents Addition of one or more of: Cardioselective BB or Long-acting CCB Diabetes without Nephropathy DHP: dihydropyridine Combinations of an ACE Inhibitor with an ARB are specifically not recommended in the absence of proteinuria CHEP 2012
  • 12. HYPERTENSION WITH CO-EXISTING CARDIOVASCULAR DISEASES  AHA/ACC Guidelines say: Treat to <130/80  2010 ICSI guideline: <140/90  Lower Achieved BP has been associated with no benefit or worsened outcomes in post hoc analysis of trials  INVEST – HTN with DM and CAD  ONTARGET – HTN with Vascular disease or DM  I-PRESERVE – HTN with Diastolic CHF N Engl J Med 2008;359:2456–67, JAMA July 7,2010;304(1)61-68, NEJM 358:1547-1559
  • 13. a) Hypertension with CCF CHEP 2012 Beta-blockers used in clinical trials were bisoprolol, carvedilol and metoprolol. If additional therapy is needed: • Diuretic (Thiazide for hypertension; Loop for volume control) • for CHF class II-IV or post MI and selected patients with LV dysfunction (see notes): Aldosterone Antagonist Systolic cardiac dysfunction • ACEI and Beta blocker • if ACEI intolerant: ARB Titrate doses of ACEI or ARB to those used in clinical trials If ACEI and ARB are contraindicated: Hydralazine and Isosorbide dinitrate in combination If additional antihypertensive therapy is needed: • ACEI / ARB Combination • Long-acting DHP-CCB (Amlodipine) Non dihydropyridine CCB
  • 14. b) Hypertension with ischaemic heart disease: • Caution should be exercised when combining a non DHP-CCB and a beta-blocker • If abnormal systolic left ventricular function: avoid non DHP-CCB (Verapamil or Diltiazem) • Dual therapy with an ACEI and an ARB are not recommended in the absence of refractory heart failure • The combination of an ACEi and CCB is preferred 1. Beta-blocker 2. Long-acting CCB Stable angina ACEI are recommended for most patients with established CAD* ARBs are not inferior to ACEI in IHD Short-acting nifedipine *Those at low risk with well controlled risk factors may not benefit from ACEI therapy CHEP 2012
  • 15. c) Hypertension with Bradycardia  Nifidipine & ACEI are preferable drugs.  Better to avoid β-blockers, verapamil, diltiazem d) Hypertension with peripheral vascular disease  Better to use Ca++ channel blocker & Vasodilators. Cochrane Review 2009, Goodman Gilman 12th ed
  • 17. HYPERTENSION IN THE ELDERLY  JNC7 and other Guidelines say: Treat to <140/90  High Risk Conditions: Treat to <130/80
  • 18. HYVET- HYPERTENSION IN THE VERY ELDERLY TRIAL  Only HTN RCT in Patients ≥80 years  N=3850 mean age 83 years, mean SBP 173 mm Hg  Goal SBP<150 mm Hg, mean achieved SBP =143 mm Hg  Placebo vs perendipril/indapamide  18 month BP separation = -15/6 mmHg N Engl J Med 2008; 358(18):1887-98.
  • 20. TREATMENT  Check and follow BP while standing  Remember diet/lifestyle changes  Treat patients with SBP >160 with medications (start with thiazide or ACE or Ca channel blockers)  Target BP in those over 80 years: 150  Recognize that patients with DBP <60 or PP >50 have a higher risk of CV events, but not clear if this can be modified
  • 21. HYPERTENSION IN CHRONIC KIDNEY DISEASE
  • 22. HYPERTENSION IN CKD  Guidelines say: Treat to <130/80  Evidence says: No renal or cardiovascular benefit in this overall group  Long term renal benefit in patients with proteinuria (>300mg/dl)  New ICSI guideline: <140/90, consider <130/80 in patients with proteinuria
  • 23. Treatment CHEP 2012 Chronic kidney disease and proteinuria * ACEI/ARB: Bilateral renal artery stenosis ACEI or ARB (if ACEI intolerant) Combination with other agents Additive therapy: Thiazide diuretic. Alternate: If volume overload: loop diuretic Target BP: < 140/90 mmHg * albumin:creatinine ratio [ACR] > 30 mg/mmol or urinary protein > 500 mg/24hr Monitor serum potassium and creatinine carefully in patients with CKD prescribed an ACEI or ARB Combinations of a ACEI and a ARB are specifically not recommended in the absence of proteinuria
  • 24. xxRecurrent stroke prevention MI = myocardial infarction; CAD=coronary artery disease; Aldo Ant = aldosterone antagonist. *Based on benefits from outcome studies or existing guidelines, the compelling indication is managed in parallel with the BP. JNC 7. JAMA. 2003;289:2560-2672. xxChronic kidney disease xxxxxDiabetes xxxxHigh CAD risk xxxPost-MI xxxxxHeart failure Aldo AntCCBARBACE Inhibitor Beta- Blocker Diuretic Recommended DrugsHigh-Risk Condition With Compelling Indication* JNC 7: COMPELLING INDICATIONS FOR INDIVIDUAL DRUG CLASSES
  • 26. HYPERTENSIVE CRISIS  Systolic blood pressure >220 and diastolic >120mmHg.  HYPERTENSIVE EMERGENCY: is severe hypertension with acute impairment of an organ system. In these conditions, the blood pressure (BP) should be lowered aggressively over minutes to hours.  HYPERTENSIVE URGENCY: the BP is a potential risk but has not yet caused acute end-organ damage. These patients require BP control over several days to weeks.
  • 27.  ACCELERATED HYPERTENSION: recent significant increase over baseline blood pressure, with vascular damage on fundoscopic examination, such as flame- shaped hemorrhages or soft exudates, but without papilledema.  Presence of papilledema indicates MALIGNANT HYPERTENSION.
  • 28. TREATMENT Weigh benefits of decreasing BP against risks of decreasing end-organ perfusion. Important steps include: - Appropriately evaluating patients with an elevated BP - Correctly classifying the hypertension - Determining aggressiveness of therapy An important point to remember in the management of the patient with any degree of BP elevation is to "treat the patient and not the number."
  • 29. TREATMENT  Initial considerations:  Place patient who is not in distress in a quiet room and reevaluate after an initial interview. BP may fall below critical levels after relaxation without specific treatment.  Consider the context of the elevated BP (e.g, severe pain)  Screen for end-organ damage- admit and rapidly lower of BP using iv meds which depend on the end-organ system damaged.  Patients without evidence of end-organ effects may be discharged with follow–up.
  • 30. DRUGS  Once the diagnosis of hypertension is made and end- organ damage confirmed, the BP should be lowered by about 25% of the mean arterial pressure.  There are 2 main classes of drugs: -Vasodilators -Adrenergic inhibitors
  • 31. VASODILATORS DRUG DOSAGE ONSET/DU ADV.EFFE Nitroprusside 0.25-10mcg/kg/min Instant/1-2min. Thiocyanate, cyanide poisoning Nitroglycerine 5-100mcg/min 1-5min/3-5min Flushing,headache, methemoglobin Nicardipine 5-15mg/hr 5-10min/1-4hr Tachycardia, flushing. Avoid-heart failure Hydralazine 10-20mg 5-15min/3-8hr Flushing, tachycardia, avoid- Aortic diss, MI Enalapril 10-40mg IM,1.25- 5MG1Vq6hr 20-30min/6hr Hypotension,renal failure, hyperkalemia Fenoldopam 0.1-0.3mcg/kg/min 5min/10-15min Flushing, headache, tachycardia
  • 32. DRUG DOSAGE ONSET/DUR ADV.EFF Labetalol (a+b blocker) 20-80mgiv bolus every 10 min,2mg.min iv infusion 5-10min/3-6hrs Heart block,ortho hypotension.avoid- heart failure,asthma Esmolol (b-1 selective blocker) 200-500 mcg/kg/min for 4min,then 150- 300mcg/kg/min 1-2min/10-20min Hypotension,avoid- heart failure,asthma Phentolamine (a1 blocker) 5-15mg iv 1-2min/3-10min Tachycardia, flushing, headache ADRENERGIC INHIBITORS
  • 33. ORAL DRUGS DRUG DOSAGE ONSET/DURATION ADV. EFF. CAPTOPRIL (ACE inhibitor) 6.25-25MG q 6hrs. 15-30min/6 hrs. Hypotension in high renin states CLONIDINE (a2 agonist-centrally acting) 0.1-0.2 mg hrly, Upto max 0.8mg in 24hrs. 30-60min/6-12hrs. Sedation, bradycardia, dry mouth LABETALOL 100-200mg q 12hrs 30-120min/8-12hrs Heart failure, heart block, bronchospasm
  • 35. TREATMENT OF HYPERTENSION IN OTHER SITUATIONS a) Hypertension in children and adolescent  Life style modification, if fail - pharmacological therapy should be started  Dosage of antihypertensive medication should be smaller and adjusted very carefully for children.  ACE inhibitor & A-II receptor blocker should not be used in pregnant mother  Use of anabolic steroid for body building & smoking strictly prohibited.
  • 36. b) Hypertension in Pregnancy  In the 2nd & 3rd trimester, antihypertensive agents often are not indicated unless the Diastolic BP exceeds 100 mm Hg.  Drugs used are methyldopa, Beta-blocker, CCB in order of preference.  Hydralazine (Parenteral) & prazosin may be used.  Should not be used: ACEI, A-II Receptor blocker, Diuretics, Nitroprusside
  • 37. c) Hypertension with Hormone replacement therapy  Presence of hypertension is not contraindicated for post menopausal estrogen replacement therapy.  Frequent follow up should be advised .
  • 38. D) HYPERTENSION IN DYSLIPIDAEMIA:  Common co-existence & demand aggressive management of both conditions.  High dose thiazides, loop diuretics & beta blockers may transiently increase total cholesterol, still has significant reduction CV morbidity & sudden death. So should be used without hesitation.
  • 39. E) HYPERTENSION WITH ASTHMA & COPD:  Ca++ channel blocker is the preferable drug.  ACEI are safe in most patients with asthma.  A-II receptor blocker may be used if cough is trouble some problem after using ACEI.  Contraindications: β-blocker should not be used in patient with asthma except in special circumstances. Goodman Gilman 12th ed
  • 40. F) HYPERTENSION WITH CVD: Treat extreme BP elevation (systolic > 220 mmHg, diastolic > 120 mmHg) by 15-25% over the first 24 hour with gradual reduction after. •If eligible for thrombolytic therapy treat very high BP (>185/110 mmHg) Acute ischemic Stroke Avoid excessive lowering of BP which can exacerbate ischemia CHEP 2012
  • 41. G) HYPERTENSION WITH LIVER DISEASE: All Antihypertensive drugs can be used except methyldopa H) HYPERTENSION WITH GOUT All hypertensive drugs can be used But all Diuretics can increase serum uric acid level. So diuretics should be avoided if possible. Contraindications: diuretics
  • 42. I) HYPERTENSION WITH PSORIASIS: β-Blocker and ACEI aggravate psoriasis. So better to avoid them. J) HYPERTENSION WITH SCLERODERMA WITH REYNAUD'S PHENOMENON Nifedipine and prostacycline infusion may occasionally helpful in patient with severe Reynaud's phenomenon.

Editor's Notes

  1. ICSI – institute of clinical systems improvement
  2. Chep - Canadian Hypertension Education Program
  3. 1. Persons with diabetes mellitus should be treated to attain systolic blood pressure of lower than130 mmHg (Grade C) and diastolic blood pressure of less than 80 mmHg (Grade A). (These target blood pressure levels are the same as the blood pressure treatment thresholds.)Combination therapy using two first-line agents may also be considered as initial treatment of hypertension (Grade B) if the SBP is 20 mmHg above the target or if DBP is 10 mmHg above the target. However caution should be exercised in patients in whom a substantial fall in blood pressure is more likely or poorly tolerated (e.g. elderly patients, patients with autonomic neuropathy). 2. For persons with cardiovascular or kidney disease, including microalbuminuria or with cardiovascular risk factors in addition to diabetes and hypertension, an ACE inhibitor or an ARB is recommended as initial therapy (Grade A). 3. For persons with diabetes and hypertension not included in the above recommendation, appropriate choices include (in alphabetical order): ACE inhibitors (Grade A), angiotensin receptor blockers (Grade B), dihydropyridine CCBs (Grade A) and thiazide/thiazide-like diuretics (Grade A).4. If target blood pressures are not achieved with standard-dose monotherapy, additional antihypertensive therapy should be used. For persons in whom combination therapy with an ACE inhibitor is being considered, a dihydropyridine CCB is preferable to hydrochlorothiazide (Grade A).
  4. 1. Persons with diabetes mellitus should be treated to attain systolic blood pressure of lower than130 mmHg (Grade C) and diastolic blood pressure of less than 80 mmHg (Grade A). (These target blood pressure levels are the same as the blood pressure treatment thresholds.)Combination therapy using two first-line agents may also be considered as initial treatment of hypertension (Grade B) if the SBP is 20 mmHg above the target or if DBP is 10 mmHg above the target. However caution should be exercised in patients in whom a substantial fall in blood pressure is more likely or poorly tolerated (e.g. elderly patients, patients with autonomic neuropathy). 2. For persons with cardiovascular or kidney disease, including microalbuminuria or with cardiovascular risk factors in addition to diabetes and hypertension, an ACE inhibitor or an ARB is recommended as initial therapy (Grade A). 3. For persons with diabetes and hypertension not included in the above recommendation, appropriate choices include (in alphabetical order): ACE inhibitors (Grade A), angiotensin receptor blockers (Grade B), dihydropyridine CCBs (Grade A) and thiazide/thiazide-like diuretics (Grade A).4. If target blood pressures are not achieved with standard-dose monotherapy, additional antihypertensive therapy should be used. For persons in whom combination therapy with an ACE inhibitor is being considered, a dihydropyridine CCB is preferable to hydrochlorothiazide (Grade A).
  5. AHA – american heart associationACC – american college of cardiology
  6. In 2008, the HYVET trial specifically looked at patients over 80 with almost 4000 patients from europe, china, and other countries. Patients had bps between 160-199 (after 2 months off of all antihypertensive medications) and were randomized to either indapamide, a thiazide type diuretic, or placebo; patients were given additional therapy with an ace inhibitor or placebo if bps remained above target. As in prior studies, the primary endpoint was stroke.